Literature DB >> 24184290

Bacterial counts from five over-the-counter probiotics: are you getting what you paid for?

Ellie J C Goldstein1, Diane M Citron2, Marina C Claros2, Kerin L Tyrrell2.   

Abstract

There is concern that the bacterial colony counts present at the time of manufacture and listed on the probiotic package may not be reflective of the numbers viable colonies at the time of purchase and patient consumption thereby diminishing efficacy. We performed a colony count study of three separate samples of five different probiotics purchased from three different stores: Bifidobacterium infantis (Align(®)); Lactobacillus acidophilus CL1285(®) and Lactobacillus casei LBC80R(®) (Bio-K+(®)); Lactobacillus rhamnosus GG (Culturelle(®)); Saccharomyces boulardii (Florastor(®)) and "L. acidophilus" and "Lactobacillus helveticus" (Lactinex(®)). Approximately 1 g of powder of each (Lactinex(®) tablets were crushed before testing) was reconstituted in sterile distilled water, serial 10-fold dilutions were prepared and plated in duplicate onto blood agar plates, with incubation for 48 h in an anaerobic chamber (except the Saccharomyces which was incubated aerobically) after which colony counts were performed. The Florastor(®) packaging did not state an expected concentration and was found to have 9.2 × 10(9)-1.3 × 10(10) CFU/g. Lactinex(®), Align(®), Bio-K+(®), and Culturelle(®) had viable colony counts that were similar to those stated on the package.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Lactobacillus; Probiotics; Saccharomyces

Mesh:

Substances:

Year:  2013        PMID: 24184290     DOI: 10.1016/j.anaerobe.2013.10.005

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  4 in total

1.  Predictors of Clostridium difficile infection and predictive impact of probiotic use in a diverse hospital-wide cohort.

Authors:  Martha L Carvour; Shane L Wilder; Keenan L Ryan; Carla Walraven; Fares Qeadan; Meghan Brett; Kimberly Page
Journal:  Am J Infect Control       Date:  2018-09-08       Impact factor: 2.918

2.  Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.

Authors:  Jason C Sniffen; Lynne V McFarland; Charlesnika T Evans; Ellie J C Goldstein
Journal:  PLoS One       Date:  2018-12-26       Impact factor: 3.240

Review 3.  Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use.

Authors:  Ravina Kullar; Stuart Johnson; Lynne V McFarland; Ellie J C Goldstein
Journal:  Antibiotics (Basel)       Date:  2021-04-09

4.  Validating bifidobacterial species and subspecies identity in commercial probiotic products.

Authors:  Zachery T Lewis; Guy Shani; Chad F Masarweh; Mina Popovic; Steve A Frese; David A Sela; Mark A Underwood; David A Mills
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.